- Home
- LLYVK vs TLX Comparison
LLYVK vs TLX Comparison
Compare LLYVK & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVK
- TLX
- Stock Information
- Founded
- LLYVK 1991
- TLX 2015
- Country
- LLYVK United States
- TLX Australia
- Employees
- LLYVK 1100
- TLX N/A
- Industry
- LLYVK Broadcasting
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- LLYVK Industrials
- TLX Health Care
- Exchange
- LLYVK Nasdaq
- TLX Nasdaq
- Market Cap
- LLYVK 6.9B
- TLX 5.7B
- IPO Year
- LLYVK N/A
- TLX N/A
- Fundamental
- Price
- LLYVK $72.95
- TLX $16.99
- Analyst Decision
- LLYVK
- TLX Strong Buy
- Analyst Count
- LLYVK 0
- TLX 1
- Target Price
- LLYVK N/A
- TLX $22.00
- AVG Volume (30 Days)
- LLYVK 341.3K
- TLX 20.6K
- Earning Date
- LLYVK 01-01-0001
- TLX 01-01-0001
- Dividend Yield
- LLYVK N/A
- TLX N/A
- EPS Growth
- LLYVK N/A
- TLX 798.14
- EPS
- LLYVK 0.27
- TLX 0.09
- Revenue
- LLYVK N/A
- TLX $484,687,790.00
- Revenue This Year
- LLYVK $7.29
- TLX N/A
- Revenue Next Year
- LLYVK N/A
- TLX N/A
- P/E Ratio
- LLYVK $267.97
- TLX $183.81
- Revenue Growth
- LLYVK N/A
- TLX 55.85
- 52 Week Low
- LLYVK $33.50
- TLX $13.61
- 52 Week High
- LLYVK $81.66
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- LLYVK 45.13
- TLX N/A
- Support Level
- LLYVK $71.48
- TLX N/A
- Resistance Level
- LLYVK $78.02
- TLX N/A
- Average True Range (ATR)
- LLYVK 2.02
- TLX 0.00
- MACD
- LLYVK -0.74
- TLX 0.00
- Stochastic Oscillator
- LLYVK 19.19
- TLX 0.00
About LLYVK Liberty Media Corporation
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.